231 related articles for article (PubMed ID: 16123474)
1. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study.
Rossing K; Schjoedt KJ; Smidt UM; Boomsma F; Parving HH
Diabetes Care; 2005 Sep; 28(9):2106-12. PubMed ID: 16123474
[TBL] [Abstract][Full Text] [Related]
2. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.
Rossing K; Jacobsen P; Pietraszek L; Parving HH
Diabetes Care; 2003 Aug; 26(8):2268-74. PubMed ID: 12882847
[TBL] [Abstract][Full Text] [Related]
3. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.
Rossing K; Christensen PK; Jensen BR; Parving HH
Diabetes Care; 2002 Jan; 25(1):95-100. PubMed ID: 11772908
[TBL] [Abstract][Full Text] [Related]
4. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.
Schjoedt KJ; Rossing K; Juhl TR; Boomsma F; Tarnow L; Rossing P; Parving HH
Kidney Int; 2006 Aug; 70(3):536-42. PubMed ID: 16775595
[TBL] [Abstract][Full Text] [Related]
5. Beneficial impact of spironolactone in diabetic nephropathy.
Schjoedt KJ; Rossing K; Juhl TR; Boomsma F; Rossing P; Tarnow L; Parving HH
Kidney Int; 2005 Dec; 68(6):2829-36. PubMed ID: 16316360
[TBL] [Abstract][Full Text] [Related]
6. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.
Nielsen SE; Persson F; Frandsen E; Sugaya T; Hess G; Zdunek D; Shjoedt KJ; Parving HH; Rossing P
Diabet Med; 2012 Aug; 29(8):e184-90. PubMed ID: 22268920
[TBL] [Abstract][Full Text] [Related]
7. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.
Jacobsen P; Andersen S; Rossing K; Hansen BV; Parving HH
Nephrol Dial Transplant; 2002 Jun; 17(6):1019-24. PubMed ID: 12032191
[TBL] [Abstract][Full Text] [Related]
8. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
Jacobsen P; Andersen S; Jensen BR; Parving HH
J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333
[TBL] [Abstract][Full Text] [Related]
9. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
van den Meiracker AH; Baggen RG; Pauli S; Lindemans A; Vulto AG; Poldermans D; Boomsma F
J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
[TBL] [Abstract][Full Text] [Related]
10. Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis.
Hou J; Xiong W; Cao L; Wen X; Li A
Clin Ther; 2015 Sep; 37(9):2086-2103.e10. PubMed ID: 26254276
[TBL] [Abstract][Full Text] [Related]
11. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study.
Rossing K; Christensen PK; Hansen BV; Carstensen B; Parving HH
Diabetes Care; 2003 Jan; 26(1):150-5. PubMed ID: 12502672
[TBL] [Abstract][Full Text] [Related]
12. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
Jacobsen P; Andersen S; Rossing K; Jensen BR; Parving HH
Kidney Int; 2003 May; 63(5):1874-80. PubMed ID: 12675866
[TBL] [Abstract][Full Text] [Related]
13. Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial.
Schjoedt KJ; Astrup AS; Persson F; Frandsen E; Boomsma F; Rossing K; Tarnow L; Rossing P; Parving HH
Diabetologia; 2009 Jan; 52(1):46-9. PubMed ID: 18974967
[TBL] [Abstract][Full Text] [Related]
14. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial.
Saklayen MG; Gyebi LK; Tasosa J; Yap J
J Investig Med; 2008 Apr; 56(4):714-9. PubMed ID: 18382267
[TBL] [Abstract][Full Text] [Related]
15. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment.
Rossing P; Tarnow L; Boelskifte S; Jensen BR; Nielsen FS; Parving HH
Diabetes; 1997 Mar; 46(3):481-7. PubMed ID: 9032106
[TBL] [Abstract][Full Text] [Related]
16. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy.
Tarnow L; Rossing P; Jensen C; Hansen BV; Parving HH
Diabetes Care; 2000 Dec; 23(12):1725-30. PubMed ID: 11128341
[TBL] [Abstract][Full Text] [Related]
17. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy.
Lacourcière Y; Bélanger A; Godin C; Hallé JP; Ross S; Wright N; Marion J
Kidney Int; 2000 Aug; 58(2):762-9. PubMed ID: 10916100
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.
Esteghamati A; Noshad S; Jarrah S; Mousavizadeh M; Khoee SH; Nakhjavani M
Nephrol Dial Transplant; 2013 Nov; 28(11):2823-33. PubMed ID: 24009294
[TBL] [Abstract][Full Text] [Related]
19. Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.
Van Buren PN; Adams-Huet B; Nguyen M; Molina C; Toto RD
Clin J Am Soc Nephrol; 2014 Feb; 9(2):295-301. PubMed ID: 24408116
[TBL] [Abstract][Full Text] [Related]
20. Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial.
Schjoedt KJ; Christensen PK; Jorsal A; Boomsma F; Rossing P; Parving HH
Nephrol Dial Transplant; 2009 Nov; 24(11):3343-9. PubMed ID: 19561152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
